# How does SS-31 (Elamipretide) support mitochondrial function in heart failure?

Canonical source: https://retacompare.com/research/how-does-ss-31-elamipretide-support-mitochondrial-function-in-heart-failure

Peptide Longevity Q&A · 2026-04-01


    Research indicates that SS-31 (Elamipretide) improves mitochondrial function and survival in models of heart failure by addressing early mitochondrial alterations associated with contractile dysfunction. This peptide may slow the progression of cardiac remodeling and dysfunction linked to chronic cardiac troponin I phosphorylation.

 What the research shows

The study published in the American Journal of Physiology examined the effects of chronic cardiac troponin I (cTnI) phosphorylation on cardiac performance in transgenic mouse models. Researchers generated three lines of mice with varying levels of phosphomimetic cTnIS43/45D replacement to investigate the impact on cardiac function. The study found that higher levels of cTnISD replacement led to accelerated deterioration in cardiac performance, highlighting the relationship between cTnI phosphorylation and contractile dysfunction.

 Why it matters for longevity

Understanding the role of mitochondrial function in heart failure is crucial for longevity research. Mitochondria are vital for energy production and cellular health, and their dysfunction is often linked to aging and various diseases. SS-31 (Elamipretide) appears to target early mitochondrial changes that occur before significant remodeling, suggesting potential applications in preserving cardiac function and overall healthspan in aging populations.

 Key findings at a glance

Chronic cTnI phosphorylation leads to contractile dysfunction in cardiac myocytes.

Transgenic mice with cTnISD replacement exhibited progressive deterioration in cardiac performance.

Early mitochondrial alterations were noted before extensive remodeling occurred.

SS-31 (Elamipretide) improved survival and slowed cardiac remodeling in models.

Differences in mitochondrial ultrastructure and increased oxidative stress were observed in cTnISD mice.

 How SS-31 (Elamipretide) works (background)

SS-31 (Elamipretide) is a peptide designed to target mitochondria and enhance their function. In research models, it has been shown to improve mitochondrial dynamics and reduce oxidative stress, which are critical factors in maintaining cellular health. By addressing early mitochondrial dysfunction linked to cardiac troponin I phosphorylation, SS-31 may help mitigate the progression of heart failure and support overall cardiac health.

 Safety, caveats, and what we don't yet know

While the findings suggest potential benefits of SS-31 (Elamipretide) in improving cardiac function and mitochondrial health, further research is necessary to fully understand its mechanisms and long-term effects. The study primarily utilized transgenic mouse models, and results may not directly translate to human populations. Additional studies are needed to explore the safety and efficacy of SS-31 in diverse patient groups.

 Bottom line

SS-31 (Elamipretide) has shown promise in supporting mitochondrial function and slowing cardiac dysfunction in research models, indicating its potential role in addressing heart failure and enhancing longevity.

 Related questions

 Can SS-31 (Elamipretide) enhance recovery after cardiac events?

Research suggests that SS-31 may improve mitochondrial function, which could aid recovery after cardiac events, though more studies are needed to confirm these effects in clinical settings.

 What role does mitochondrial function play in aging?

Mitochondrial function is critical for energy production and cellular health. Impaired mitochondrial function is associated with aging and various age-related diseases, making it a key target for longevity interventions.

 How does oxidative stress affect heart health?

Oxidative stress can lead to cellular damage and is implicated in heart disease progression. Targeting oxidative stress through interventions like SS-31 may help protect heart health and improve outcomes.

 Source: PubMed · Am J Physiol Heart Circ Physiol · published 2026-04-01.

## Sources

- PubMed · Am J Physiol Heart Circ Physiol: https://pubmed.ncbi.nlm.nih.gov/41711592/